Luyan Pharmaceutical announced that the cumulative deviation value of the company's stock trading price increase exceeded 20% in two consecutive trading days, which was an abnormal fluctuation in stock trading. It has been verified that there are no corrections or additions to the information disclosed earlier. Recently, the company's business situation is normal, there have been no major changes in the internal and external business environment, the company has found no recent public media reports of undisclosed major information that may or have had a significant impact on the company's stock trading price, the company, controlling shareholders and actual controllers have no important matters that should be disclosed about the company, or important matters in the planning stage. During the period of abnormal stock fluctuations, the controlling shareholders or actual controllers did not trade the company's shares.

Luyan Pharmaceutical announced that the cumulative deviation value of the company's stock trading price increase exceeded 20% in two consecutive trading days, which was an abnormal fluctuation in stock trading. It has been verified that there are no corrections or additions to the information disclosed earlier. Recently, the company's business situation is normal, there have been no major changes in the internal and external business environment, the company has found no recent public media reports of undisclosed major information that may or have had a significant impact on the company's stock trading price, the company, controlling shareholders and actual controllers have no important matters that should be disclosed about the company, or important matters in the planning stage. During the period of abnormal stock fluctuations, the controlling shareholders or actual controllers did not trade the company's shares.